ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
-0,31%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
71.080,40
-0,52%
Brent Oil
83,125
-0,48%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) Notícias

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNPX
DataHoraFonteTítuloCódigoCompanhia
15/05/202418:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202410:00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202410:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202410:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202409:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202412:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
21/12/202319:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
19/12/202311:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202311:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
14/11/202319:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
13/11/202319:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
03/11/202318:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
02/11/202310:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202310:00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
07/09/202310:00PR Newswire (US)Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyNASDAQ:SNPXSynaptogenix Inc
19/07/202310:00PR Newswire (US)Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
13/07/202310:00PR Newswire (US)Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceNASDAQ:SNPXSynaptogenix Inc
22/06/202318:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
15/05/202317:51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNPXSynaptogenix Inc
31/03/202317:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
21/03/202318:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SNPXSynaptogenix Inc
07/03/202311:00PR Newswire (US)Synaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesNASDAQ:SNPXSynaptogenix Inc
18/01/202318:29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SNPXSynaptogenix Inc
28/12/202218:16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SNPXSynaptogenix Inc
28/12/202208:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SNPXSynaptogenix Inc
16/12/202211:00PR Newswire (US)Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
18/11/202211:00PR Newswire (US)Synaptogenix Announces $15 Million Private Placement with Existing InvestorsNASDAQ:SNPXSynaptogenix Inc
19/10/202210:00PR Newswire (US)Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022NASDAQ:SNPXSynaptogenix Inc
28/09/202212:50PR Newswire (US)Synaptogenix Welcomes Lecanemab Phase 3 Trial ResultsNASDAQ:SNPXSynaptogenix Inc
25/08/202217:34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNPXSynaptogenix Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNPX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
LUPA3
LUPATECH ON
BOV
CASH3
Meliuz S.A ON
BOV
INBR32
Inter &
BOV
GOLL4
GOL PN
BOV
LWSA3
LOCAWEB ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados